Brief: Bolt Biotherapeutics Announces Clinical Collaboration With Bristol Myers Squibb To Study BDC-1001 In Combination With Opdivo For Treatment Of HER2-Expressing Solid Tumors
08/09/2021 12:37
Sept 8 (Reuters) - Bristol-Myers Squibb Co BMY.N :
* BOLT BIOTHERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH
BRISTOL MYERS SQUIBB TO STUDY BDC-1001 IN COMBINATION WITH
OPDIVO® FOR TREATMENT OF HER2-EXPRESSING SOLID TUMORS
* BOLT BIOTHERAPEUTICS INC - WILL BE RESPONSIBLE FOR COSTS
ASSOCIATED WITH TRIAL EXECUTION
* BOLT BIOTHERAPEUTICS INC - COMBINATION DOSE ESCALATION IS
EXPECTED TO START LATER IN 2021
Source text for Eikon: ID:nGNX4Db4cb
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))